Background: Although ypStage has been known as a strong prognosticator of recurrence and survival, the detailed interaction of ypT and ypN classification on a survival rate has never been evaluated.
Methods: Between October 2001 and December 2007, in total, 960 patients with locally advanced rectal cancer were enrolled retrospectively at 3 centers. Five-year overall survival (OS) and disease-free survival (DFS) rate were calculated for each ypTN classification.
Results: The ypT classification interacted with ypN classification to affect survival in most categories. Patients with ypStage 0 and I cancers showed a >90% 5-year OS (ypStage 0, 96.5%; ypStage I, 92.9%; P = .346) and 5-year DFS (ypStage 0, 90.2%; ypStage I, 90.7%; P = .879). Among ypStage III subgroups, large differences in 5-year OS (ypStage IIIA, 90.1%; ypStage IIIB, 68.3%; ypStage IIIC, 40.5%; P < .001) and 5-year DFS (ypStage IIIA, 74.8%; ypStage IIIB, 55.1%; ypStage IIIC, 12.3%; P < .001) were observed. OS and DFS in patients with ypStage IIIA disease were similar to or greater than those in patients with ypStage IIA or IIB/IIC disease. Four patient risk groups were defined: 1) low (ypT0-isN0, ypT1N0, ypT2N0), 2) intermediate (ypT0-2N1, ypT3N0), 3) moderately high (ypT0-2N2, ypT3N1, ypT4N0), and 4) high risk (ypT3N2, ypT4N1-2). Risk grouping showed a narrower range of survival rate compared with ypStage grouping.
Conclusions: ypStage in rectal cancer, defined according to the 7th edition of the American Joint Committee on Cancer staging system, predicts survival for most ypNT classifications. However, patients with ypStage I rectal cancer have a similar prognosis to those with ypStage 0 cancer, and risk grouping reflects more precise survival outcomes than ypStage.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/cncr.27507 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Lymph-node ratio as a risk factor for recurrence following neoadjuvant docetaxel, cisplatin, and 5-fluorouracil therapy for locally advanced esophageal squamous cell carcinoma.
Esophagus
January 2025
Department of Gastroenterological Chemotherapy, Japanese Foundation for Cancer Research, Cancer Institute Hospital, 3-8-31 Ariake, Koto-Ku, Tokyo, 135-8550, Japan.
Background And Purpose: It remains unclear whether the lymph-node ratio (LNR) is a relevant factor for the risk of recurrence following neoadjuvant chemotherapy (nCT) with docetaxel, cisplatin, and 5-fluorouracil (DCF), which is a new standard of care for locally advanced esophageal squamous cell carcinoma (ESCC) in Japan. This study aimed to evaluate the clinical utility of LNR as a risk factor for recurrence.
Materials And Methods: We retrospectively analyzed 75 patients who underwent nCT-DCF followed by curative surgery for resectable ESCC.
Characterizing Patients with ypT0N1 Gastric Adenocarcinoma Within the AJCC Staging System.
Ann Surg Oncol
December 2024
Division of Gastrointestinal Surgical Oncology, Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Introduction: The standard of care for gastric cancer in the United States involves perioperative chemotherapy. While most post-therapy pathologic staging results are concordant (i.e.
View Article and Find Full Text PDFModified FOLFOX6 with Cetuximab versus with Radiotherapy in Neoadjuvant Treatment of Locally Advanced Rectal Cancer: A Single-Center, Prospective, Randomized Controlled Trial.
Biol Pharm Bull
October 2024
Department of Gastrointestinal Surgery, The Affiliated Ganzhou Hospital of Nanchang University.
Article Synopsis
- A clinical trial assessed the effectiveness of neoadjuvant chemotherapy using targeted agents for locally advanced rectal cancer patients with specific gene mutations.
- Patients were randomly assigned to two treatment groups: one receiving chemotherapy with radiotherapy, and the other with the drug cetuximab; both groups later underwent surgery.
- Results showed no significant differences in the success rates of tumor removal (R0 resection) and other outcomes between the two groups, but the cetuximab group had lower complications, suggesting it may be a better treatment approach.
A case of successful conversion surgery for unresectable gallbladder cancer treated with durvalumab in combination with gemcitabine plus cisplatin.
Clin J Gastroenterol
October 2024
Department of Surgery and Science, Faculty of Medicine, Academic Assembly, University of Toyama, 2630, Toyama, Sugitani, 930-0194, Japan.
We report a rare case of a patient with initially unresectable gallbladder cancer who underwent conversion surgery with durvalumab in combination with gemcitabine plus cisplatin and achieved an R0 resection. A 68 year-old woman was found to have gallbladder cancer and multiple enlarged lymph nodes around the suprapancreatic rim and hepatic hilum invading the proper hepatic artery on computed tomography. The diagnosis was cT3cN2cM0, cStage IVB.
View Article and Find Full Text PDFLocally advanced rectal cancer in a young adult affected with dyskeratosis congenita (Zinsser-Cole-Engman syndrome): a case report.
Surg Case Rep
September 2024
Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Kumamoto, 860-8556, Japan.
Article Synopsis
- Dyskeratosis congenita (DKC) is a genetic disease characterized by skin pigmentation issues, nail problems, and leukoplakia, with around 8-10% of patients developing cancers, including colorectal cancer.
- A case study involved a 25-year-old man with DKC who was diagnosed with locally advanced rectal cancer, receiving total neoadjuvant therapy (chemotherapy followed by chemoradiation), which initially reduced the tumor.
- Despite a near-complete response, the patient experienced tumor regrowth five months later and underwent a total pelvic exenteration surgery, after which he has remained cancer-free for one year.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!